Oruka Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Oruka Therapeutics, Inc. (ORKA), a Delaware corporation, filed this Current Report on Form 8-K on April 30, 2026, covering events occurring between April 27 and April 30, 2026. The filing primarily addresses the completion of a public offering of common stock and provides preliminary liquidity data as of March 31, 2026.
Key Financial Metrics
- Liquidity: The Company estimates cash, cash equivalents, and investments were approximately $496 million as of March 31, 2026. This figure is preliminary and subject to revision.
- Capital Raised: The Company completed the sale of 9,660,000 shares of Common Stock at a public offering price of $72.50 per share.
- Revenue and Profit: The filing does not provide finalized revenue, profit, or cash flow data for the three months ended March 31, 2026. The Company explicitly states these results are not yet finalized.
- Debt and Margins: No specific debt levels or margin data are disclosed in this filing.
Material Changes and Events
The primary material event is the successful closing of a registered offering on April 30, 2026. The Company entered into an Underwriting Agreement on April 28, 2026, with representatives including Leerink Partners, TD Securities, Goldman Sachs, Stifel, and Guggenheim. The offering utilized a shelf registration statement (File No. 333-294852) declared effective on April 10, 2026. An option was granted to underwriters to purchase up to an additional 1,449,000 shares within 30 days.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the estimated cash position as of March 31, 2026. Management cautions that these estimates are based on currently available information and are not a substitute for GAAP financial statements. The Company references risk factors detailed in its Annual Report on Form 10-K for the year ended December 31, 2025, noting that actual results may differ due to known and unknown uncertainties. No specific operational guidance or future earnings outlook is provided in this document.
Investor Verification Checklist
- Verify the final audited cash, cash equivalents, and investment balances for the quarter ended March 31, 2026, once the Company finalizes its accounting books.
- Confirm the exercise status of the 30-day underwriter option to purchase an additional 1,449,000 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific indemnification terms and underwriting discounts.
- Monitor the upcoming Form 10-Q for the quarter ended March 31, 2026, for finalized revenue and operating expense data.